EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors

Naoto Wakabayashi, Shiro Watanabe, Satoshi Takeuchi, Takahiro Tsuchikawa, Yamato Munakata, Kenji Hirata, Rina Kimura, Junki Takenaka, Hiroshi Ishii, Kohsuke Kudo

Annals of Nuclear Medicine · 2025-07 · 39 (7) · 696-706

DOI: 10.1007/s12149-025-02044-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, online erschienen am 05.04.2025. Verfasst von Naoto Wakabayashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Lutetium, Radiation Dosage. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In peptide receptor radionuclide therapy (PRRT) using lutetium-177-labeled DOTA-Tyr3-octreotate ([ 177 Lu] DOTATATE), isolation is required until the external dose rate at 1 m (EDR-1 m) from the body surface falls below the regulatory standards of each country. While it is known that renal function influences EDR-1 m reduction within 180 min post-administration, the factors affecting EDR-1 m on the day following administration (Late EDR-1 m) remain unclear. This study aimed to identify factors influencing Late EDR-1 m after PRRT using [ 177 Lu] DOTATATE for neuroendocrine tumors and to predict Late EDR-1 m using pretreatment [ 111 In] pentetreotide single-photon emission computed tomography/computed tomography (SPECT/CT) data.

Methods

This study analyzed 111 PRRT cycles administered to 36 patients between September 2021 and August 2024. Late EDR-1 m was set as the dependent variable, whereas total radiopharmaceutical uptake (LUTtotal), dose per body weight, creatinine clearance (CCr), and albumin–bilirubin (ALBI) score were set as the independent variables in the multiple regression analysis. LUTtotal was calculated using SPECT/CT data acquired after the patient left the radiation therapy room, defining the volume of interest (VOI) as the area with SUVmean + 2SD or higher in the skeletal muscle. The VOI volume multiplied by the SUVmean was used to define LUTtotal. In addition, using [ 111 In] pentetreotide SPECT/CT data, the total radiopharmaceutical uptake (OCTtotal) was calculated in a manner similar to LUTtotal, and its correlation with LUTtotal was examined. A predictive equation for Late EDR-1 m was developed using the results of the multivariate analysis, and its performance was tested using subsequent cases between August 2024 and January 2025.

Results

The median measured Late EDR-1 m was 8.0 (range, 4.0–26.0) μSv/h. LUTtotal and dose per body weight were significantly correlated with Late EDR-1 m, whereas CCr and ALBI scores were not. Based on the results of the multivariate analysis, the predictive equation using the dose per body weight, assuming a dosage of 7400 MBq and OCTtotal, achieved a root mean square error (RMSE) of 2.24 μSv/h. In subsequent test cases, the RMSE was 3.47 μSv/h.

Conclusions

Late EDR-1 m is significantly correlated with LUTtotal and dose per body weight. It can be accurately predicted using [ 111 In] pentetreotide SPECT/CT data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideLutetiumRadiation DosageOrganometallic CompoundsRadioisotopesHumansMaleFemaleMiddle AgedAgedAdultSingle Photon Emission Computed Tomography Computed TomographyRadiotherapy Dosage

Stichwörter der Autor:innen

Neuroendocrine tumorPRRTSPECT/CT[111in] pentetreotide[177Lu] DOTATATE

Substanzen

OctreotideLutetiumLutetium-177Organometallic CompoundsRadioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, Japan.
  • Department of Diagnostic Imaging and Interventional Radiology, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-Ku, Sapporo, Hokkaido, Japan.
  • Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, Japan.
  • Department of Nuclear Medicine, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, Japan. shirow@med.hokudai.ac.jp.
  • Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, Japan. shirow@med.hokudai.ac.jp.
  • Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, Japan. shirow@med.hokudai.ac.jp.

Zitieren

APA

Wakabayashi, N., Watanabe, S., Takeuchi, S., Tsuchikawa, T., Munakata, Y., Hirata, K., Kimura, R., Takenaka, J., Ishii, H., & Kudo, K. (2025). Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors. Annals of Nuclear Medicine, 39(7), 696-706. https://doi.org/10.1007/s12149-025-02044-5

Vancouver

Wakabayashi N, Watanabe S, Takeuchi S, Tsuchikawa T, Munakata Y, Hirata K, et al. Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors. Annals of Nuclear Medicine. 2025;39(7):696-706. doi:10.1007/s12149-025-02044-5

BibTeX
@article{Wakabayashi2025,
  author = {Wakabayashi, Naoto and Watanabe, Shiro and Takeuchi, Satoshi and Tsuchikawa, Takahiro and Munakata, Yamato and Hirata, Kenji and Kimura, Rina and Takenaka, Junki and Ishii, Hiroshi and Kudo, Kohsuke},
  title = {Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors},
  journal = {Annals of Nuclear Medicine},
  year = {2025},
  volume = {39},
  number = {7},
  pages = {696--706},
  doi = {10.1007/s12149-025-02044-5}
}
Kostenlos starten →